PRIMARY STUDY

Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy

Key Findings:  In patients with diabetic nephropathy already taking a renin-angiotensin inhibitor, with elevated low-density lipoprotein cholesterol (LDL-C) levels, and well-controlled blood pressure, levels of liver-type fatty acid-binding protein (L-FABP) decreased significantly after 6 months in the group taking rosuvastatin. This suggests that rosuvastatin may provide additional benefits against oxidative stress, and can reduce inflammatory systatin C levels in this patient population.